Physician profile
Anna Laura Lee
NPI 1811621717
$586.14
in general payments reported to CMS, 2019-2025
11 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.07 · 2023: $131 · 2024: $253 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $117.04 | 2024-2025 | Daxxify |
| Incyte Corporation | $100.47 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $90.27 | 2022-2024 | |
| Merz North America, INC. | $90.00 | 2024-2025 | |
| Abbvie INC. | $42.32 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.67 | 2024-2025 | Jublia, Cabtreo, Siliq |
| Biofrontera INC. | $35.01 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Verrica Pharmaceuticals INC. | $20.52 | 2025 | Ycanth |
| Almirall LLC | $19.28 | 2023 | Seysara |
| Arcutis Biotherapeutics, INC. | $14.78 | 2023 | |
| Pfizer INC. | $14.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.